US DoJ says Abbott (ABT) agrees to approx. USD 304mln settlement on allegations of infant formula

A DoJ settlement of this size over infant formula allegations fits the established pattern in which large healthcare names resolve federal claims with a one-off payment and, typically, no admission of wrongdoing; the financial channel is a discrete charge against earnings rather than a change to the operating trajectory. Episodes of this kind have tended to be absorbed quickly by diversified large-caps, with the initial equity move fading once the charge is quantified and ring-fenced, since the known number removes the open-ended liability that the market prices worst. The distinction worth drawing is between settlements that close the matter outright and those that leave parallel exposure: state-level actions, private civil suits, or related regulatory scrutiny have historically been the follow-ons that keep a legal overhang alive after the federal piece is done. The infant formula franchise has carried heightened regulatory and reputational sensitivity in past episodes, so any DOJ language on conduct, compliance undertakings, or monitorship terms matters more for the read-through than the headline figure. Worth noting next is how the company characterises the charge in its next filing, whether other parties to the allegations settle on similar terms, and whether the resolution references ongoing oversight obligations. As legal news rather than operational news, the signal is confined to the single name unless the allegations point to sector-wide practice.